FUCIDIN OINTMENT 2% 2 % — DIN 00586676
FUSIDATE SODIUM : 2 % · LEO PHARMA INC · OINTMENT · wholesale supply in Canada
Health Canada status: MARKETED
What is FUCIDIN OINTMENT 2%?
FUCIDIN OINTMENT 2% 2 % contains FUSIDATE SODIUM : 2 %. It is listed in the Health Canada Drug Product Database under DIN 00586676, held by LEO PHARMA INC, supplied as OINTMENT for TOPICAL administration. Health Canada currently lists it as marketed, status dated 31-Dec-1984. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is FUCIDIN OINTMENT 2% used for?
For use in the treatment of primary and secondary skin infections caused by sensitive strains of Staphylococcus aureus, Streptococcus spp and Corynebacterium minutissimum. Primary skin infections that may be expected to respond to treatment with FUCIDIN OINTMENT (sodium fusidate) and CREAM (fusidic acid) include: impetigo contagiosa, erythrasma and secondary skin infections such as infected wounds and infected burns. To reduce the development of drug-resistant bacteria and maintain the effectiveness of FUCIDIN OINTMENT and CREAM and other antibacterial drugs, FUCIDIN OINTMENT and CREAM should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. Appropriate culture and susceptibility studies should be performed. However, while waiting results of these studies and, if antibiotic therapy is considered to be necessary, FUCIDIN OINTMENT and CREAM may be administered to those patients in whom an infection caused by susceptible bacteria is suspected. This antibiotic treatment may subsequently require modification once these results become available. In addition, local concentrations of FUCIDIN OINTMENT and CREAM are active against other Corynebacteria spp. No cross-resistance has been observed to date between FUCIDIN and other antibiotics presently in clinical use. Resistance to FUCIDIN has readily been induced in vitro. The development of resistance has also been shown to occur in the clinical setting. Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Fusidic Acid cost around the world?
Fusidic Acid is listed on 9 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max); Czechia publishes a max producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Saudi Arabia | public | 38 | 44 | SAR███.██ |
| Bahrain | retail (max) | 13 | 14 | BHD███.██ |
| Greece | producer price (ex-factory) | 8 | 8 | EUR███.██ |
| Austria | KVP (Kassenverkaufspreis) | 4 | 7 | EUR███.██ |
| United Arab Emirates | public | 5 | 6 | AED███.██ |
| South Africa | single exit price | 6 | 6 | ZAR███.██ |
| Luxembourg | reimbursement | 5 | 5 | EUR███.██ |
| Czechia | max producer price (ex-factory) | 2 | 4 | CZK███.██ |
| United Kingdom | hospital | 4 | 4 | GBP███.██ |
98 pack listings across 85 brand entries and 8 price bases, refreshed 05 Sep 2026. Ranges span every Fusidic Acid pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Fusidic Acid in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
2 holders have a Canadian DIN containing Fusidic Acid, across 3 DINs, of which 3 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| LEO PHARMA INC | 2 | 2 | FUCIDIN CREAM 2%, FUCIDIN OINTMENT 2% | Sourceable in Canada |
| TARO PHARMACEUTICALS INC | 1 | 1 | TARO-FUSIDIC ACID | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 2 % |
|---|---|
| Dosage form | OINTMENT |
| Route | TOPICAL |
| Pack configuration (monograph) | FUCIDIN CREAM: Available in aluminium tubes of 15 g and 30 g covered with internal epoxyphenol lacquer. The tube has re-closable high density polyethylene screw cap. FUCIDIN OINTMENT: Available in aluminium tubes of 15 g and 30 g covered with internal epoxyphenol lacquer. The tube has re-closable high density polyethylene screw cap. |
| Storage | FUCIDIN CREAM: Store below 30°C. FUCIDIN OINTMENT: Store below 30°C. Use within 3 months of first opening the tube. Keep out of reach and sight of children and pets. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Substance and classification
| Active substance | Fusidic Acid |
|---|---|
| ATC code | D06AX01 |
| AHFS class | 84:04.04 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 00586676 |
|---|---|
| DIN (unpadded, as printed on some documents) | 586676 |
| Brand name | FUCIDIN OINTMENT 2% |
| Generic / active ingredient | FUSIDATE SODIUM : 2 % |
| Market authorization holder | LEO PHARMA INC |
| Health Canada schedule | Prescription |
| ATC code | D06AX01 |
| ATC anatomical main group | D — Dermatologicals |
| ATC therapeutic subgroup | D06AX |
| Current status | MARKETED |
| Status date | 31-Dec-1984 |
| Original market date | 1984-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
A small amount of FUCIDIN OINTMENT or CREAM should be applied to the lesion two to three times daily for 7-14 days. Whenever the lesion is to be covered with a gauze dressing, less frequent applications (1 or 2 daily) may be used. In impetigo contagiosa, it has been shown to be unneccessary to remove the crusts before application of FUCIDIN OINTMENT or CREAM. When required, incision and drainage of infected skin lesions should be carried out before treatment with FUCIDIN OINTMENT or CREAM.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Fusidic acid 2% cream and Sodium fusidate 2% ointment are contraindicated in patients who are hypersensitive to these drugs or to any ingredient in the formulations, including non-medicinal ingredient, or component of the container. For a complete listing, see Dosage Forms, Strengths, Composition and Packaging.
Warnings and precautions
Treatment of severe or refractory skin lesions should be supplemented with the administration of a systemic antibacterial agent. Use of topical antibiotics occasionally allows overgrowth of non-susceptible organisms. If this occurs, or irritation or sensitization develops, treatment with FUCIDIN OINTMENT or CREAM should be discontinued and appropriate therapy instituted. Prescribing FUCIDIN OINTMENT and CREAM in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and risks the development of resistant organisms. Bacterial resistance among Staphylococcus aureus has been reported to occur with the use of topical FUCIDIN. As with all antibiotics, extended or recurrent use of fusidic acid may increase the risk of developing antibiotic resistance. Limiting therapy with topical fusidic acid to no more than 14 days at a time will minimize the risk of developing resistance. FUCIDIN CREAM contains butyl hydroxyanisole, cetyl alcohol and potassium sorbate. These excipients may cause local skin reactions (e.g. contact dermatitis). Butyl hydroxyanisole may also cause irritation to the eyes and mucous membranes. FUCIDIN CREAM should therefore be used with care when applied in the proximity of the eyes. FUCIDIN OINTMENT contains cetyl alcohol and hydrous lanolin. These excipients may cause local skin reactions (e.g. contact dermatitis). FUCIDIN OINTMENT contains butylhydroxytoluene (E321) which may cause local skin reactions (e.g. contact dermatitis) or irritation to the eyes and mucous membranes. When FUCIDIN OINTMENT is used on the face; care should be taken to avoid the eyes as the excipients in the ointment may cause conjunctival irritation.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
3 of 3 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| FUCIDIN CREAM 2% | 2 % | CREAM | LEO PHARMA INC | MARKETED | 00586668 |
| TARO-FUSIDIC ACID | 2 % | CREAM | TARO PHARMACEUTICALS INC | MARKETED | 02528096 |
2 · Same class — other molecules in ATC D06AX
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Combinations Of Antibiotics | ANTIBIOTIC COLD SORE OINTMENT · ANTIBIOTIC CREAM · ANTIBIOTIC CREAM FOR KIDS · ANTIBIOTIC CREAM PLUS PAIN RELIEF · +34 more | 48 | 16 | Yes |
| Fusidic Acid | FUCIDIN CREAM 2% · FUCIDIN OINTMENT 2% · TARO-FUSIDIC ACID | 3 | 3 | Yes |
| Bacitracin | ANTIBIOTIC OINTMENT · ANTIBIOTIQUE ONGUENT · BACIGUENT FIRST AID OINTMENT · BACIGUENT FIRST AID OINTMENT 500UNITS/GM · +22 more | 33 | 2 | Yes |
| Mupirocin | BACTROBAN · BACTROBAN CREAM · BACTROBAN NASAL OINTMENT · STRAMUCIN · +1 more | 5 | 2 | Yes |
| Bacitracin, Combinations | ANTIBIOTIC OINTMENT · EXTRA STRENGTH BACITRAYCIN PLUS · OZONOL ANTIBIOTIC PLUS - OINTMENT · OZONOL ANTIBIOTIC PLUS ONT · +3 more | 7 | 0 | Not in Canada |
| Gentamicin | GARAMYCIN CREAM 0.1% · GARAMYCIN ONT 0.1% · PMS-GENTAMICIN CREAM 1MG/GM · PMS-GENTAMICIN OINTMENT 1MG/GM · +1 more | 6 | 0 | Not in Canada |
| Neomycin | AMINODERM POUDRE · CICATRIN POWDER · MYCIGUENT OINTMENT · NEOSPORIN ANTIBIOTIC CREAM · +2 more | 6 | 0 | Not in Canada |
| Ozenoxacin | OZANEX | 1 | 0 | Not in Canada |
| Retapamulin | ALTARGO | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC D06A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| D06AA | Chlortetracycline · Tetracycline | 3 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is FUCIDIN OINTMENT 2% called?
Also recorded in Canada as: FUSIDATE SODIUM (GLOBAL), SODIUM FUSIDATE (UK), FUCIDIN (UK), FUCIDIN (EU), FUCIDIN H (EU), FUCITHALMIC (EU), FUCIDIN VITA (EU), FUCIDIN INTERTOPIC (EU), FUCIDIN LEO (EU), FUCIDIN HUNGARY (EU), FUCIDIN CREAM (IN), FUCIDIN OINTMENT (IN), FUCIDIN TOPICAL OINTMENT (KR), FUCIDIN LEO PHARMA (GLOBAL), FUCIDIN TOPICAL (GLOBAL).
The same molecule, Fusidic Acid, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| BELOGENT | Latin | Czechia |
| BALAD | Latin | Saudi Arabia |
| CIDOCOMB | Latin | Bahrain, Saudi Arabia |
| DERMOFUCIN | Latin | Bahrain |
| Diprogenta Creme | Latin | Austria |
| Diprogenta Salbe | Latin | Austria |
| Fucidin | Latin | Bahrain, South Africa |
| Fucidin H | Latin | Bahrain, South Africa |
| FUCIDIN H CREAM | Latin | Saudi Arabia |
| Fucidin Salbe | Latin | Austria |
| FUCITHALMIC VISCOUS EYE DROPS | Latin | Saudi Arabia |
| FUSIBACT-B CREAM | Latin | Saudi Arabia |
| EZADERM | Latin | Bahrain |
| FUCICORT | Latin | Czechia |
| Fucidin Cream | Latin | South Africa |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.